Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by BlaineBorgon Jun 19, 2021 11:09am
127 Views
Post# 33416606

RE:RE:RE:RE:RE:RE:RE:The IPF and Chronic Cough study is now on the back burner.

RE:RE:RE:RE:RE:RE:RE:The IPF and Chronic Cough study is now on the back burner.

What we saw was Mackie smacking the c-rap out of Algernon Pharmaceuticals with their analysis of the COVID-19 Phase II Topline data readout. If the CEO crawls back to them with another PP that would be yet another astonishingly unfortunate thing to witness. I mean Mackie sank Algernon's battleship! Warranted...maybe?! You lie with dogs you catch fleas, but maybe that was the underplay for the overplay anyway? Meaning, the inside job was someone (KM)/others plugged in, knew that a hit piece was coming and made a killing on the downfall of the stock. What's certain is that the reputation of the company has been severely damaged. Primarily due to the inability to get to data readouts in a reasonable time frame with one excuse after the other. You can't expect the market to fall in love with your endless stories but don't deliver the end of the story as stated. People got other shiit to do as well with their money other than throwing it down a wishing well. Missing data readouts one after the other is a death knell to your corporate reputation. The market is buying into a timeline to data. The CEO has stated a bunch of times how "EVERYBODY WANTS IN AT PHASE 2". Hindsight being 20/20, does anyone here wish they had sat out on the IPF and Chronic Cough story?


BB

 
<< Previous
Bullboard Posts
Next >>